EHA 2022 | Unmet needs in T-ALL: targeted therapies & managing relapse
David Teachey
• 12 Jun 2022
David Teachey, MD, The Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, outlines unmet needs in T-cell acute lymphoblastic leukemia (T-ALL). Dr Teachy highlights the importance of developing more effective therapies to treat patients who relapse after first-line therapy and emphasizes the potential of immunotherapy in this disease. In addition, he explains that it is important to better understand the biology of T-ALL to develop novel targeted therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
